Full-Time

Vice President

Clinical Science

Updated on 4/23/2024

Revolution Medicines

Revolution Medicines

201-500 employees

Develops precision oncology therapies

Biotechnology

Compensation Overview

$265,000 - $350,000Annually

+ Equity

Senior, Expert

San Carlos, CA, USA

Required Skills
Communications
Management
Requirements
  • M.D. (or non-US equivalent) or MD/PhD, board certified.
  • Training in medical oncology preferred.
  • A minimum of 10-15 years of experience in the pharmaceutical/biotech industry or academia, preferably the majority in oncology drug development.
  • A minimum of 5-10 years of leadership and management experience.
  • Extensive experience in protocol design, implementation, and management of global phase 1-4 clinical trials.
  • Direct experience interfacing with regulatory agencies, strong working knowledge and understanding of regulatory requirements for drug development, and preferably approval in more than one key region (ie. US, EU, Japan).
  • Outstanding knowledge of industry issues and competitive landscape in oncology.
  • Anticipates future trends and has a broad perspective of competitive landscape and regulatory implications on clinical development; ability to effectively communicate visions of possibilities and probabilities to executive management as well as cross-functional teams.
  • Excellent track record and reputation in the industry, well-networked influencer and engager who regularly leverages such relationships to extend research, development and business opportunities.
  • Experience networking with key opinion leaders in oncology and more specifically RAS and mTOR signaling pathways highly preferred.
  • Outstanding leadership, collaboration, and teamwork in cross-functional setting; comfortable with a hands-on leadership position.
  • Effective prioritization and decision making.
  • Consistently drive for results by setting aggressive but achievable goals.
  • Inspires and motivates others to the highest levels of performance and quality within the Clinical Science Organization and beyond.
  • Excellent verbal and written communication skills and collaborative interpersonal skills.
  • Travel required.
Responsibilities
  • Responsible for the delivery of clinical strategy for the pipeline.
  • Standing member of the program governance body.
  • Responsible for protocols and investigator brochures for clinical stage molecules.
  • Develop/manage infrastructure, processes, budget, etc. for the Clinical Development Organization.
  • Hire, develop, and oversee the work of direct/indirect reports within the Clinical Development Organization.
  • Drive protocol development by leading and partnering with a cross-functional team, including Research, Biometrics, Clinical Operations, Development Diagnostics, and Regulatory.
  • Represent clinical with external stakeholders including investigators, key opinion leaders, and investors.
  • Play a leadership role in the design and timely and high-quality implementation of Phase 1-4 clinical studies.
  • Play a leadership in global regulatory submission and registration.
  • Partner with cross-functional groups to map out clinical and regulatory strategies.
  • Collaborate with clinical operations on investigator selection and engagement.
  • Partner with the Research and Development Diagnostics groups to assure alignment of diagnostics strategy including patient selection and development of companion diagnostics.
  • Oversee the review, analysis, and reporting of clinical data in collaboration with biometrics to enable internal decision making and regulatory filings.
  • Lead the preparation and execution for clinical presentations at scientific conferences.

Revolution Medicines specializes in developing precision oncology therapies, particularly RAS(ON) inhibitors and RAS Companion inhibitors, with their lead product candidate, RMC-4630, currently in a Phase 1/2 clinical program targeting specific oncogenic mutations in various tumor types. The company's main focus is on developing these therapies to target specific oncogenic mutations in different tumor types, utilizing precision oncology technologies.

Company Stage

IPO

Total Funding

$1.3B

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

22%

1 year growth

50%

2 year growth

102%